We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Allopurinol in the Treatment of Neoplastic Disease Complicated by Hyperuricemia

Franco M. Muggia, MD; Thomas J. Ball Jr., MD; John E. Ultmann, MD
Arch Intern Med. 1967;120(1):12-18. doi:10.1001/archinte.1967.00300010014003.
Text Size: A A A
Published online


THE INVESTIGATION of agents suppressing the oxidative degradation of mercaptopurine1 led to the recognition of the potential clinical usefulness of the xanthine oxidase inhibitors which interfere with the final conversion of the oxypurines (hypoxanthine and xanthine) to uric acid.2 One of these compounds, allopurinol (Zyloprim), has been shown to be useful in the management of gout and hyperuricemia where inadequate control had been achieved with colchicine and uricosuric drugs.3-14 Since the reduction in serum uric acid takes place by a process of enzyme inhibition, allopurinol is effective in the presence of renal disease and it does not increase the risk of uric acid crystallization within the urinary tract.

In patients with neoplastic disease, there is often a significant increase in purine catabolism and hyperuricemia.15-17 Occasionally during the course of cancer and of leukemia or lymphoma, one may, in addition, observe gouty arthritis18 or renal calculi.19


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.